Eli Lilly

Selected news for the company - Eli Lilly, collected since 10/2017. This company shares news with COVID-19, Pfizer, Novartis, Merck, Food and Drug Administration and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/15/2021 Crwe World | Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 crweworld.com Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 Additional doses of etesevimab will be paired with existing bamlanivimab purchased by the U.S. government [15-September-2021]INDIANAPOLIS , Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part ...
9/15/2021 Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million MarketWatch ... bamlanivimab and etesevimab for administration together, in anticipation of variants such as the highly contagious Delta variant, which currently accounts for more than 98 percent of all identified COVID-19 cases in the U.S." Eli Lilly 's stock, which was still inactive in premarket trading, has run up 38.1% year to date, while the S&P 500[SPX,] has gained 18.3 ...
9/15/2021 Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 | Markets Insider Business Insider INDIANAPOLIS , Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship Q3 2021 and the remaining ...
9/15/2021 Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million forextv.com ... and etesevimab for administration together, in anticipation of variants such as the highly contagious Delta variant, which currently accounts for more than 98 percent of all identified COVID-19 cases in the U.S.” Eli Lilly ’s stock, which was still inactive in premarket trading, has run up 38.1% year to date, while the S&P 500 has gained 18.3%.Market Pulse Stories are Rapid-fire, short news bursts on ...
9/15/2021 UPDATE 1-U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy - Netscape News netscape.com 09/15/2021 11:27 (Adds details on supply, background)Sept 15 (Reuters) - Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.Lilly said ...
9/15/2021 U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy Yahoo News Reuters) -Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.Lilly said its deal with the U.S government is expected to ...
9/15/2021 U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy dailymagazine.news Reuters) -Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.Lilly said its deal with the U.S government is expected to ...
9/14/2021 Malignant Mesothelioma Market Size, Share, Trends Analysis and Growth Forecast 2026|AstraZeneca, Bristol-Myers Squibb, Roche packagingnews24.com ... help the players gain a clear understanding into the overall existing and future market situation. Key companies operating in the global Malignant Mesothelioma market include _AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly , Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical Access PDF Version of this Report at: https://www.qyresearch.com ...
9/14/2021 Serum Cancer Biomarkers Market: Analysis and In-depth study on market Size Trends, Emerging Growth Factors and Regional Forecast to 2025 packagingnews24.com ... Base Year: 2018 - Estimated Year: 2019 - Forecast Year: 2019 – 2029 Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2170152&source=atm The following manufacturers are covered: Roche Pfizer Novartis Abbott BD Merck Eli Lilly Agilent Technologies Boehringer Ingelheim AstraZeneca Bristol-Myers Squibb Novo Nordisk Allergan Gilead Segment by Regions North America Europe China Japan Segment by Type Hepatocellular Carcinoma Serum Biomarkers Lung Cancer Serum Biomarkers Pancreatic & Biliary Tract ...
9/14/2021 Digestive System Drug Market May Set New Growth Story | Novartis Pharmaceuticals, Pfizer, Sanofi, Eli Lilly instanttechnews.com ... of growth. As more companies move some or all of their applications, emerging players are poised to benefit. Some of the players from the overall coverage being profiled were Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Eli Lilly & Kunshan Rotam Reddy Pharmaceuticals. With the Digestive System Drug market forecast to grow YY% in 2020 and with X-X-X-X expected to be a big beneficiary, it is better positioned than Z ...
9/14/2021 Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases Globe Newswire ... closed an $85 million Series B financing round, led by Omega Funds. The syndicate includes Series A investor OrbiMed and new investors Omega Funds , Surveyor Capital (a Citadel company), Avoro Ventures , Casdin Capital , Pontifax , Eli Lilly and Company , Logos Capital , and Osage University Partners . Proceeds from the financing will be used to accelerate the development of the company’s innovative therapeutic programs. The need for effective neurodegenerative therapies is urgent ...
9/14/2021 GoNetwork Price Down 31.6% Over Last Week (GOT) | Daily Political Daily Political Ethic Inc. Sells 4,236 Shares of Eli Lilly and Company (NYSE:LLY) Posted by Jeff WilderEthic Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 32.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,994 shares of the company’s stock after selling 4,236 shares during the period. Ethic Inc.’s holdings in Eli Lilly and were ...
9/14/2021 Ethic Inc. Lowers Position in Eli Lilly and Company (NYSE:LLY) - American Banking News American Banking News Ethic Inc. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 32.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,994 shares of the company’s stock after selling 4,236 shares during the period. Ethic Inc.’s holdings in Eli Lilly and were worth $2,064,000 as of its most recent SEC filing.Several other hedge funds have also modified ...
9/14/2021 Life Sciences Visionaries and Innovators Come Together at Veeva Summit Connect | Markets Insider Business Insider ... made toward connected development and manufacturing. Featured sessions include:Astellas highlighting how to improve document accessibility and collaboration for greater GxP compliance. Bayer sharing early innovator insights on the value of digital clinical trials. Eli Lilly and Company explaining how to build and deploy a library of standards for streamlined data collection. Incyte sharing best practices for managing local pharmacovigilance system master file (PSMF) requirements for better global visibility. Roche ...
9/14/2021 ProQR Therapeutics N.V. (NASDAQ: PRQR) Signs Licensing and Research Agreement With Lilly for Axiomer Platform biopharmajournal.com ProQR Therapeutics N.V. (NASDAQ: PRQR) has announced a worldwide licensing and research agreement with Eli Lilly and Company to discover, produce, and commercial possible new drugs for genetic nervous and liver system disorders. As per the agreements, the companies will utilize ProQr’s novel Axiomer RNA editing platform in advancing new drug candidates towards clinical development and marketing. Axiomer allows editing of RNA nucleotides The Axiomer RNA editing tech allows ...
9/14/2021 Ethic Inc. Lowers Position in Eli Lilly and Company (NYSE:LLY) zolmax.com Ethic Inc. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 32.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,994 shares of the company’s stock after selling 4,236 shares during the period. Ethic Inc.’s holdings in Eli Lilly and were worth $2,064,000 as of its most recent SEC filing. Several other hedge funds have also modified ...
9/14/2021 Life Sciences Visionaries and Innovators Come Together at Veeva Summit Connect tmcnet.com ... made toward connected development and manufacturing. Featured sessions include: - Astellas highlighting how to improve document accessibility and collaboration for greater GxP compliance. - Bayer sharing early innovator insights on the value of digital clinical trials. - Eli Lilly and Company explaining how to build and deploy a library of standards for streamlined data collection. - Incyte sharing best practices for managing local pharmacovigilance system master file (PSMF) requirements for better global visibility. - Roche ...
9/14/2021 In Extended Rant, Joe Scarborough Demands We Tax The Rich crooksandliars.com ... a lobbyist's concern? Because over the past few years, there are corporations that have paid zero taxes in a year and just over the past couple of years, that includes Amazon, Chevron, Avis, Delta, Eli Lilly , GM, Goodyear, Halliburton, Honeywell, IBM, Netflix, Occidental Petroleum, Fedex, Nike, on and on and on." (Hey Joe, they're not just paying zero. Most of them are getting massive tax refunds, too!) "Are moderates really ...
9/14/2021 Investment Management of Virginia LLC Sells 148 Shares of Eli Lilly and Company (NYSE:LLY) - Transcript Daily transcriptdaily.com Investment Management of Virginia LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,610 shares of the company’s stock after selling 148 shares during the period. Investment Management of Virginia LLC’s holdings in Eli Lilly and were worth $2,435,000 at ...
9/14/2021 Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast–2026 brajnewsmagazine.org ... barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. List of Companies: - Becton - Dickinson and Company (U.S.) - Pfizer Inc. (U.S.) - Teva Pharmaceuticals Industries Ltd. (Israel) - Eli Lilly and Company (U.S.) - Baxter International, Inc. (U.S.) - Schott AG (Germany) - Gerresheimer (Germany) - Ypsomed (Switzerland) - B. Braun Melsungen (Germany). Injectable Drug Delivery Devices Market Dynamics Injectable Drug Delivery Devices Market Drivers - Growing incidence of chronic ...